Theragnostics’ proprietary clinical lead, THG-001 (THP-PSMA), is being developed with our Galli® technology to provide valuable diagnostic information on the status of patients with prostate cancer.

A Phase I clinical trial of THG-001 was completed during 2016 and results of the trial have been published in the Journal of Nuclear Medicine.

An article by Dr Greg Mullen, CEO, was featured in  Diagnostic Imaging Europe in November 2017.

Diagnostic for pancreatic cancer – early development.
Therapy for pancreatic cancer – early development.
Feasibility studies for therapy based on THP-PSMA.
NET diagnostic – early development.
Partnered development program.
Partnered development program.

Further updates will be added in due course.